Clarteis

Executive Summary

Clarteis is a French medical device company founded in 2012 and headquartered in Paris. The company has developed the exciplex® device, a compact, monochromatic excimer light source designed for targeted phototherapy of localized autoimmune skin conditions such as Alopecia Areata, Vitiligo, and Psoriasis. The device offers dermatologists a precise and effective treatment option, potentially improving patient outcomes and convenience compared to traditional phototherapy systems. Clarteis operates in the dermatology medical device market, which is growing due to rising prevalence of skin disorders and increasing demand for non-invasive therapies. While the company has not publicly disclosed funding or revenue, its technology addresses significant unmet needs in dermatology, particularly for conditions like vitiligo and alopecia areata where treatment options are limited. Clarteis remains privately held, with no disclosed stage or valuation, indicating it may be in early commercial or clinical development phases. The company's success hinges on regulatory approvals, clinical evidence, and market adoption of the exciplex device. With a focused product and a clear target market, Clarteis has potential to carve out a niche in the phototherapy segment, though competition from established players and alternative treatments exists. The company's trajectory will depend on its ability to demonstrate clinical efficacy, secure reimbursement, and expand geographically beyond Europe.

Upcoming Catalysts (preview)

• TBDFDA 510(k) clearance for exciplex device in the US40% success
• TBDPublication of pivotal clinical trial results for vitiligo or alopecia areata60% success
• TBDStrategic partnership with a major dermatology network or pharmaceutical company50% success